Biogen MS Drug Could Lift Takeout Potential

Published On: April 12th, 2011

An oral MS drug from Biogen could increase the likelihood that the maker of Tysabri, which counts Carl Icahn as an investor, is taken over. Laura Mandaro interviews RBC Capital Markets’ Michael Yee from the American Academy of Neurology’s conference.

The rest is here:
Biogen MS Drug Could Lift Takeout Potential/a>

STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.

Did you know:

African-American women have the highest death rates from heart disease, breast and lung cancer, stroke, and pregnancy among women of all racial and ethnic backgrounds

hardwickun7 : Seth Godin: Patient capital, markets that work and ending the endless emergency of poverty http://t.co/V9piJXQ8

2012-05-22T01:47:03Z - Reply - View Tweet
clauseltnkaht0 : The annual capital markets roundup is in room N259-N261 at 10am.

2012-05-22T01:41:24Z - Reply - View Tweet
ecclestonzllyi4 : The annual capital markets roundup is in room N259-N261 at 10am.

2012-05-22T01:40:50Z - Reply - View Tweet
ethos_jobs : Executive Job - Financial Analyst - http://t.co/DzIIcVvE

2012-05-22T01:06:48Z - Reply - View Tweet
Gary_USBonds : Attending Rothschild Caesarea Capital Markets Risk Conference in Tel Aviv. Always an annual highlight.

2012-05-22T01:05:05Z - Reply - View Tweet
GPickholz : Attending Rothschild Caesarea Capital Markets Risk Conference in Tel Aviv. Always an annual highlight.

2012-05-22T01:04:10Z - Reply - View Tweet
Mahmut_Albayrak : ?MKB head says capital markets in need of urgent consolidation http://t.co/Ezb7LWr7 via @todayszamancom

2012-05-22T01:02:06Z - Reply - View Tweet

Biogen Idec Sues Other MS Drug Makers
The biotech is suing the makers of multiple sclerosis drugs that, like its own Avonex treatment, are forms of beta interferon. ..
A.M. Vitals: FDA Panel Unanimously Recommends Novartis MS Drug
Also: price transparency for health-care costs; production woes at drug manufacturing plants; the genetics of autism. ..
New Caution Urged Over Sole Oral MS Drug On the Market
The FDA says the only oral multiple-sclerosis drug on the market shouldn’t be used in patients with a recent history of stroke or some heart problems. ..
FDA Talks, Wall Street Listens and MS Drug Maker’s Stock Plunges
Shares of a small New York drug maker plunged today after FDA staff raised concerns about its multiple sclerosis drug, the first pill intended to help those suffering from the chronic condition to walk faster. The ups and downs of stock in the drug maker, Acorda Therapeutics, are all too familiar for anyone who follows..
Teva Shares Fall After MS Drug Falls Short in Study
Developing new drugs is a tricky business. Teva Pharmaceutical Industries and Active Biotech got a tough reminder of that today; shares in the companies fell after they said their experimental multiple-sclerosis drug, laquinimod, missed the main goal of a major study. ..
A.M. Vitals: Sanofi Suggests Working Group to Look at Genzyme’s MS Drug
Also: food makers to offer new front-of-package label; Glaxo whistleblower; Harvard Med School gets $30 million for primary care. ..

Orshe